Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Significant benefits in non-small-cell lung cancer from customizing erlotinib treatment

15.09.2008
Lung cancer patients whose tumors carry specific genetic mutations can achieve significantly longer survival when treated with targeted therapies such as erlotinib, Spanish researchers report.

Investigators from the Spanish Lung Cancer Group conducted the largest-ever study to examine the benefits of customizing lung cancer treatment based on mutations in the epidermal growth factor receptor (EGFR) gene.

At the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm they report that patients with the mutations survived for almost two years on average when treated with erlotinib.

“For the first time in lung cancer management, doctors are able, by testing EGFR mutations, to identify a subgroup of patients (between 15-22% according to our experience) who can obtain a new survival landmark in advanced non-small-cell lung cancer, with oral EGFR inhibitors like erlotinib,” said Prof. Rafael Rosell, who presented the new data at the meeting.

The Spanish group took tumor biopsies from 2,312 patients with advanced non-small-cell lung cancer and screened them for two common mutations in the gene for epidermal growth factor receptor, which can be a cause of lung cancer.

The two mutations they screened for were a deletion in exon 19 of the receptor’s tyrosine kinase domain, and a mutation in exon 21. Tumors with EGFR mutations are more frequently seen in people who have never smoked and in women.

The group identified 307 patients who carried the EGFR mutations. Each was treated with erlotinib.

Based on data from 193 patients, the mean survival was 22 months, Prof. Rosell reported. For women, the mean survival was 28 months; for men, 17 months. Mean time to progression was 12 months overall, and was longer in women than in men.

The researchers saw a response to treatment in 71% of patients, including 24 patients who experienced a complete response. The probability of response was twice as high in patients aged 61-71 years and in patients with the exon 19 deletion.

“Therefore non-small-cell lung cancers with EGFR mutations display a two-to-three-fold increment in outcome in comparison with non-small-cell lung cancers treated with chemotherapy, in which median survival is 11 months, time-to-progression is 5 months, and response 20-30%,” Prof. Rosell said.

“These results are a new clinical discovery. The impressive survival and response are undeniable. This is a new landmark of treatment in non-small-cell lung cancer, and the first tangible target for customizing treatment with EGFR tyrosine kinase inhibitors.”

Vanessa Pavinato | alfa
Further information:
http://www.esmo.org

More articles from Health and Medicine:

nachricht Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Foods of the future
15.08.2018 | Georg-August-Universität Göttingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

Im Focus: Lining up surprising behaviors of superconductor with one of the world's strongest magnets

Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur

What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

2018 Work Research Conference

25.07.2018 | Event News

 
Latest News

Staying in Shape

16.08.2018 | Life Sciences

Diving robots find Antarctic seas exhale surprising amounts of carbon dioxide in winter

16.08.2018 | Earth Sciences

Protein droplets keep neurons at the ready and immune system in balance

16.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>